Abstract
The “Vaccines and Related Biological Products Advisory Committee 17 December 2020 Meeting Briefing Document”, formulated by the FDA, reported three cases of swelling in areas previously injected with HA filler, introducing the possible relationship between a COVID-19 vaccine and adverse events in areas previously injected with HA fillers. The aim of this research is to report a case of an adverse event following a COVID-19 vaccine in a patient previously injected with facial filler. Furthermore, a scoping review on the same topic was performed. The research was carried out on the electronic databases PubMed, Cochrane Library, Web of Science, Google Scholar and Scopus. The selection process identified four articles as eligible for inclusion in the review. Nineteen patients, including the described case report, who experienced an adverse event following a COVID-19 vaccine in areas previously injected with facial filler were identified. Adverse events following a COVID-19 vaccine in patients previously injected with facial filler appear to be rare. A high BDDE cross-linking rate and/or a low-molecular-weight hyaluronic acid filler may have a higher tardive adverse event rate when triggered.
Highlights
On 31 December 2019, the Wuhan Municipal Health Commission (China) reported a cluster of pneumonia cases that were induced by a novel coronavirus called SARS-CoV2
The “Vaccines and Related Biological Products Advisory Committee 17 December 2020 Meeting Briefing Document”, formulated by the FDA, reported three cases of swelling in areas previously injected with hyaluronic acid (HA) filler, introducing the possible relationship between a COVID-19 vaccine and adverse events in areas previously injected with HA fillers
Nineteen patients, including the described case report, who experienced an adverse event following a COVID-19 vaccine in areas previously injected with facial filler were identified
Summary
On 31 December 2019, the Wuhan Municipal Health Commission (China) reported a cluster of pneumonia cases that were induced by a novel coronavirus called SARS-CoV2. This infection spread quickly across the globe in 2020 and by 11 March 2020, the World Health Organization (WHO) had announced that the COVID-19 outbreak was a new pandemic [1]. Every country underwent lockdowns of various durations and applied limitations based on the occupation of the Intensive Care Units (ICU) by COVID-19 infected patients [2,3,4,5]. During the COVID-19 outbreak, several specialties modified their care delivery model from conventional (face to face) to virtual or remote care, performed via telemedicine [6,7,8,9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
